Systemic Immunosuppression for Recurrent Uveitis

Indications for Systemic Therapy

The American College of Rheumatology indicates that patients with recurrent uveitis, defined as three episodes over 5 years, require systemic immunosuppression to prevent vision-threatening complications and reduce relapse frequency 1, 2
Systemic therapy is also recommended for patients with repeated topical steroid dependence, as it demonstrates an inability to maintain remission without treatment 1, 2
The presence of cumulative complications, such as posterior synechiae, cataract, glaucoma, and macular edema, increases the risk of structural damage and necessitates systemic therapy 1, 3

Methotrexate is the first-choice systemic immunosuppressant, with a typical dosing of 15-25 mg weekly for adults, and is used as a steroid-sparing agent to prevent future relapses 1, 2, 4, 5
The European League Against Rheumatism recommends starting with subcutaneous methotrexate for better bioavailability 4

If methotrexate proves ineffective or poorly tolerated after 3 months, the American College of Rheumatology recommends adding or switching to monoclonal anti-TNF antibodies, such as adalimumab or infliximab 1, 2, 3
Alternative options include mycophenolate mofetil or azathioprine, though these are generally second-line 6, 7

The minimum treatment duration is at least 2 years of completely inactive disease off all topical steroids before considering tapering, as recommended by the American Academy of Ophthalmology 1, 8
Monitoring requirements include ophthalmologic examination every 3 months minimum while on therapy, and follow-up within 1 month after any medication change 4, 5

Young age, particularly males with early disease onset, is a poor prognostic indicator that strengthens the indication for immediate systemic therapy 6
Posterior segment involvement, even if mild, and structural complications, such as posterior synechiae, band keratopathy, and elevated intraocular pressure, also necessitate aggressive systemic immunosuppression 7, 5
Bilateral disease and macular or optic disc edema are additional critical prognostic factors that require close monitoring and aggressive treatment 5, 2

For patients with Behçet's syndrome, azathioprine, cyclosporine-A, or interferon-alpha are evidence-based options, and monoclonal anti-TNF antibodies may be used for refractory cases 6, 7
For patients with JIA-associated uveitis, methotrexate remains first-line, and there is a lower threshold for adding biologics given high complication rates 1, 3, 2